"Designing Growth Strategies is in our DNA"

U.S Secondary Hyperparathyroidism (SHPT) Treatment Market Size, Share & Industry Analysis, By Drug Class (Calcimimetics, Vitamin D Analogues, and Phosphate Binders), By Distribution Channel (Hospital & Retail Pharmacies, Online Channels, and Others), and Region Forecast 2019-2032

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI101664

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Prevalence of Secondary Hyperparathyroidism, 2018
    2. Distribution of Secondary Hyperparathyroidism Patients by Treatment Type – Surgery, Drugs   and Others, 2018
    3. Key Industry Developments – Mergers, Acquisitions and Partnerships
    4. Pipeline Analysis
    5. Reimbursement Scenario
    6. Cost Burden of Secondary Hyperparathyroidism
  5. U.S. Secondary Hyperparathyroidism Treatment Market Analysis, Insights, and Forecast, 2015-2026
    1. Market Analysis, Insights, and Forecast – By Drug Class
      1. Calcimimetics
      2. Vitamin D Analogues
      3. Phosphate Binders
    2. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital & Retail Pharmacies
      2. Online Pharmacies
      3. Others
    3. Market Analysis, Insights, and Forecast – By Region
      1. West
      2. Midwest
      3. South
      4. Northeast
  6. Competitive Analysis
    1. Key Industry Developments
    2. U.S. Market Share Analysis (2018)
    3. Competition Dashboard
    4. Comparative Analysis – Major Players
    5. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Teva Pharmaceutical Industries Ltd.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. Genzyme Corporation (Sanofi)
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. AbbVie Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. Cipla Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Dr. Reddy’s Laboratories Ltd.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      6. Amgen Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      7. OPKO Health, Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
  7. Strategic Recommendations
Read Less

Table 01: U.S. Secondary Hyperparathyroidism Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2015–2026

Table 02: U.S. Secondary Hyperparathyroidism Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2015–2026

Table 03: U.S. Secondary Hyperparathyroidism Treatment Market Revenue (US$ Mn) Forecast, by Region, 2015–2026

U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market Size, Share and Global Industry Trend Forecast till 2032
  • REPORT UPDATE
    IN PROCESS
  • 2019-2032
    (In Process)
  • 2023
    (In Process)
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase